



General Assembly

Substitute Bill No. 5212

February Session, 2010

* _____HB05212INS__031710_____*

**AN ACT CONCERNING INSURANCE COVERAGE FOR THE
TREATMENT OF BLEEDING DISEASES.**

Be it enacted by the Senate and House of Representatives in General Assembly convened:

1 Section 1. (NEW) (*Effective January 1, 2011*) (a) As used in this
2 section:

3 (1) "Bleeding disease specialty home care pharmacy" means a
4 pharmacy licensed under section 20-594 of the general statutes that
5 provides to persons with bleeding diseases:

6 (A) A full range of clotting medications and access to on-site
7 pharmacy staff;

8 (B) Ancillary services, equipment and supplies necessary for home
9 infusions of clotting medications;

10 (C) Home care services, including, but not limited to, visiting
11 nurses;

12 (D) Biohazard waste disposal services;

13 (E) Access twenty-four hours each day to client support services
14 that include, but are not limited to, assistance with third-party
15 insurance reimbursement and third-party insurance benefits
16 coordination; and

17 (F) Ongoing client education.

18 (2) "Bleeding disease" means a medical condition characterized by a
19 deficiency or absence of one or more essential blood clotting proteins
20 in the human blood, including, but not limited to, all forms of
21 hemophilia, Von Willebrand disease and any other bleeding disease
22 that results in uncontrollable bleeding or abnormal blood clotting.

23 (3) "Clotting medications" means intravenously administered
24 medicines manufactured from human plasma or recombinant
25 biotechnology techniques, approved for distribution by the federal
26 Food and Drug Administration and used for the treatment and
27 prevention of symptoms associated with bleeding diseases. The term
28 includes:

29 (A) Factor VIIa, Factor VIII and Factor IX products;

30 (B) Von Willebrand Factor products;

31 (C) Prothrombin complex concentrates;

32 (D) Activated prothrombin complex concentrates; and

33 (E) Other products approved by the federal Food and Drug
34 Administration for the treatment of bleeding diseases and associated
35 inhibitors.

36 (b) Each individual health insurance policy providing coverage of
37 the type specified in subdivisions (1), (2), (4), (11) and (12) of section
38 38a-469 of the general statutes, that is delivered, issued for delivery,
39 renewed, amended or continued in this state shall provide (1) access to
40 and coverage for medically necessary services, equipment and
41 supplies provided by a bleeding disease specialty home care
42 pharmacy, and (2) coverage for all clotting medications prescribed by a
43 licensed physician if such policy provides coverage for outpatient
44 prescription drugs approved by the federal Food and Drug
45 Administration.

46 Sec. 2. (NEW) (*Effective January 1, 2011*) (a) As used in this section:

47 (1) "Bleeding disease specialty home care pharmacy" means a
48 pharmacy licensed under section 20-594 of the general statutes that
49 provides to persons with bleeding diseases:

50 (A) A full range of clotting medications and access to on-site
51 pharmacy staff;

52 (B) Ancillary services, equipment and supplies necessary for home
53 infusions of clotting medications;

54 (C) Home care services, including, but not limited to, visiting
55 nurses;

56 (D) Biohazard waste disposal services;

57 (E) Access twenty-four hours each day to client support services
58 that include, but are not limited to, assistance with third-party
59 insurance reimbursement and third-party insurance benefits
60 coordination; and

61 (F) Ongoing client education.

62 (2) "Bleeding disease" means a medical condition characterized by a
63 deficiency or absence of one or more essential blood clotting proteins
64 in the human blood, including, but not limited to, all forms of
65 hemophilia, Von Willebrand disease and any other bleeding disease
66 that results in uncontrollable bleeding or abnormal blood clotting.

67 (3) "Clotting medications" means intravenously administered
68 medicines manufactured from human plasma or recombinant
69 biotechnology techniques, approved for distribution by the federal
70 Food and Drug Administration and used for the treatment and
71 prevention of symptoms associated with bleeding diseases. The term
72 includes:

73 (A) Factor VIIa, Factor VIII and Factor IX products;

- 74 (B) Von Willebrand Factor products;
- 75 (C) Prothrombin complex concentrates;
- 76 (D) Activated prothrombin complex concentrates; and
- 77 (E) Other products approved by the federal Food and Drug
78 Administration for the treatment of bleeding diseases and associated
79 inhibitors.

80 (b) Each group health insurance policy providing coverage of the
81 type specified in subdivisions (1), (2), (4), (11) and (12) of section 38a-
82 469 of the general statutes, that is delivered, issued for delivery,
83 renewed, amended or continued in this state shall provide (1) access to
84 and coverage for medically necessary services, equipment and
85 supplies provided by a bleeding disease specialty home care
86 pharmacy, and (2) coverage for all clotting medications prescribed by a
87 licensed physician if such policy provides coverage for outpatient
88 prescription drugs approved by the federal Food and Drug
89 Administration.

This act shall take effect as follows and shall amend the following sections:		
Section 1	January 1, 2011	New section
Sec. 2	January 1, 2011	New section

INS *Joint Favorable Subst.*